공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

LUM001 : 신약 인사이트와 시장 예측(2030년)

LUM001- Emerging Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품 코드 974750
페이지 정보 영문 60 Pages
가격
US $ 2,750 ₩ 3,108,000 PDF (Single User License)
US $ 5,500 ₩ 6,216,000 PDF (Site License)
US $ 8,250 ₩ 9,324,000 PDF (Global License)


LUM001 : 신약 인사이트와 시장 예측(2030년) LUM001- Emerging Insight and Market Forecast - 2030
발행일 : On Demand Report 페이지 정보 : 영문 60 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

LUM001은 장의 담즙산을 순환으로 되돌리는 정단측 나트륨 의존성 담즙산 수송체(ASBT) 억제제입니다. LUM001은 1일 1회 경구 정제로 혈청 담즙산을 줄여 많은 담즙울체성 간질환과 관련된 중증 가려움과 진행성 간장애를 경감하기 위한 새로운 치료법을 제공할 가능성이 있습니다. LUM001은 원발성 담즙성 간경변, 진행성 가족성 간내 담즙울체, 알라질증후군, 원발성 경화성 담관염을 포함한 4개 희귀한 담즙울체성 간질환에 대해 미국식품의약국(FDA)으로부터 희귀의약품 지정을 받고 있습니다.

세계에서의 광범위한 연구와 증가하는 헬스케어비에 의해 향후 몇 년간 알라질증후군 시장 시나리오는 변화할 것으로 보입니다. 그로 인해 시장 규모가 확대하고, 제약회사가 보다 많은 시장에 참여할 수 있게 됩니다.

기업과 학술 관계자는 과제 평가와 함께 LUM001의 우위성에 영향을 미칠 가능성이 있는 기회를 모색하고 있습니다. 개발중인 치료법은 병상을 치료/개선하기 위한 새로운 어프로치에 초점을 맞추고 있습니다.

알라질증후군을 위한 기타 신제품은 LUM001과 시장에서 경쟁하고 있으며, 조만간 새로운 치료법이 출시되어 시장에 큰 영향을 미칠 것입니다.

규제 마일스톤, 개발 활동 및 몇 가지 중요한 연구 결과는 LUM001의 현재 개발 시나리오를 제공합니다.

2020-2030년간 LUM001의 예측 매출 데이터를 상세하게 분석하여 LUM001의 전체적인 시나리오를 확인하고, 치료 포트폴리오에 관한 의사결정 프로세스에 있어서 클라이언트를 지원합니다.

7개 주요 시장의 알라질증후군 임상시험약에 대해 종합적으로 다룹니다. 2020-2030년간 조사기간 중 미국, 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국) 및 일본 7개 주요 시장의 LUM001 개요를 제품 상세와 함께 제공합니다. 제품 상세에는 작용기서, 투여량과 관리, 합성 경로, 규제 마일스톤을 포함한 연구개발 활동 및 기타 개발 활동이 포함됩니다. 또한 시장 예측, SWOT 분석, 시장의 경쟁 동향 및 기타 새로운 치료법 등 향후 시장 동향을 제공합니다.

목차

제1장 약제 개요

  • 제품 상세
  • 작용기서
  • 투여량과 관리
  • 연구개발 활동
    • 임상 개발
    • 안전성과 유효성
  • 기타 개발 활동

제2장 시장 평가

  • 주요 7개국 시장 분석
  • 미국 시장
  • 독일 시장
  • 프랑스 시장
  • 이탈리아 시장
  • 스페인 시장
  • 영국 시장
  • 일본 시장

제3장 SWOT 분석

제4장 애널리스트의 견해

제5장 시장 경쟁 동향

제6장 기타 새로운 치료법

제7장 부록

제8장 보고서 구입 옵션

KSM 20.12.16

List of Tables

  • Table 1 LUM001, Description
  • Table 2 LUM001, Clinical Trial Description
  • Table 3 LUM001, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of LUM001
  • Figure 2 Patent Details, LUM001
  • Figure 3 LUM001, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 LUM001, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 LUM001, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 LUM001, Japan Market Size from 2020 to 2030 (in Millions USD)

"LUM001- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Alagille syndrome in 7 Major Markets. A detailed picture of the LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

LUM001 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), which recycles intestinal bile acids back into the circulation. By reducing serum bile acids with a once-daily oral tablet, LUM001 may offer a novel therapeutic approach for alleviating the severe itching and progressive liver damage associated with many cholestatic liver diseases. LUM001 has received Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development in four rare cholestatic liver diseases including primary biliary cirrhosis; progressive familial intrahepatic cholestasis; Alagille syndrome; and primary sclerosing cholangitis.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around LUM001.
  • The report contains forecasted sales for LUM001 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Alagille syndrome.
  • The report also features the SWOT analysis with analyst insights and key findings of LUM001.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUM001 Analytical Perspective by DelveInsight

  • In-depth LUM001 Market Assessment

This report provides a detailed market assessment of LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • LUM001 Clinical Assessment

The report provides the clinical trials information of LUM001 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Alagille syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence LUM001 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Alagille syndrome are giving market competition to LUM001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of LUM001.
  • Our in-depth analysis of the forecasted sales data of LUM001 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LUM001.

Key Questions:

  • Which company is developing LUM001 along with the phase of the clinical study?
  • What is the technology utilized in the development of LUM001?
  • What is the product type, route of administration and mechanism of action of LUM001?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUM001 development?
  • What are the key designations that have been granted to LUM001?
  • What is the forecasted market scenario of LUM001?
  • What is the history of LUM001 and what is its future?
  • What is the forecasted sales of LUM001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to LUM001?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

Back to Top
전화 문의
F A Q